On June 18, Hims & Hers Health rose 5.68% in regular trading, trading at $34.05/share, with turnover of approximately $250 million. The stock extended its multi-session rebound driven by a combination of favorable catalysts.

On the news front, Goldman Sachs raised its global GLP-1 weight-loss drug market forecast, projecting the market to reach $114 billion by 2030, up from its prior estimate of $101 billion. The upgrade was driven by accelerating adoption of oral GLP-1 therapies, strengthening demand outside the U.S., and improving drug accessibility and affordability. As a telehealth platform with exposure to the weight management category, Hims & Hers stands to benefit from the expanding addressable market.

Additionally, recent sales tracking data showed that three out of the past four weeks delivered year-over-year positive sales growth, sending a clear signal of marginal improvement in business fundamentals and reigniting bullish sentiment among investors.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)